🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. Amlodipine

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule terminated

    1 trial

  2. Amlodipine

    China SXT Pharmaceuticals

    Essential Hypertension

    phase 3 small molecule active

    1 trial

  3. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Roche Registration Limited

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  4. Anagrelide Hydrochloride

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  5. Anakinra 100mg and Placebo Depo-Medrone

    United Therapeutics Europe Ltd

    Gout

    phase 3 small molecule completed

    1 trial

  6. Anifrolumab, Anifrolumab Placebo

    AstraZeneca AB

    Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria

    phase 3 small molecule active

    1 trial

  7. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  8. Anterior Capsulotomy

    China SXT Pharmaceuticals

    Obsessive-Compulsive Disorder

    phase 3 other active

    1 trial

  9. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  10. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  11. Anti-PD-1 antibody drug named Serplulimab

    China SXT Pharmaceuticals

    Locally Advanced Rectal Cancer (LARC)

    phase 3 small molecule active

    1 trial

  12. Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  13. Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab terminated

    1 trial

  14. Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  15. Apitox - pure honeybee toxin

    Apimeds Pharmaceuticals US

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  16. Apitox, purified honeybee toxin, lyophilized in saline

    Apimeds Pharmaceuticals US

    Osteoarthritis of the Knee

    phase 3 mab completed

    1 trial

  17. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen Technology (Ireland) UC

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  18. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial

  19. Armstrong Albuterol Sulfate Inhalation Aerosol

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  20. Aspirin 75 mg daily

    Century Therapeutics

    Intracerebral Haemorrhage

    phase 3 small molecule active

    1 trial

  21. Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure, Aspirin® protect 300 mg Magensaftresistente Tablette Acetylsalicylsäure, Placebo of Aspirine 100 mg protect, placebo of aspirin 300 mg protect

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  22. Astragalus Membranaceus

    China SXT Pharmaceuticals

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  23. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources